Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor.

Cell Signal

Department of Physiology, University of Manitoba, and Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, 351 Tache Avenue, Winnipeg, Manitoba, Canada.

Published: April 2011

The extracellular-regulated kinase (ERK1/2) is a key conduit for transduction of signals from growth factor receptors to the nucleus. Previous work has shown that ERK1/2 activation in response to IGF-1 may require the participation of G proteins, but the role of the receptor tyrosine kinase in this process has not been clearly resolved. This investigation of IGF-1 receptor function was therefore designed to examine the contribution of the receptor tyrosine kinase to ERK1/2 activation. Phosphorylation of ERK1/2 in smooth muscle cells following treatment with IGF-1 was not blocked by pretreatment with AG1024 or picropodophylin, inhibitors of the IGF-1 receptor tyrosine kinase. Likewise, IGF-1 activated ERK1/2 in cells expressing a kinase-dead mutant of the IGF-1 receptor. ERK1/2 activation was unaffected by the phosphatidylinositol 3-kinase inhibitor LY-294002, but was sensitive to inhibitors of Src kinase, phospholipase C and Gβγ subunit signalling. Treatment with αIR-3, a neutralizing monoclonal antibody, also stimulated ERK1/2 phosphorylation without concomitant activation of the receptor tyrosine kinase. Phosphoprotein mapping of IGF-1 and αIR-3 treated cells confirmed that antibody-induced ERK1/2 phosphorylation occurred in the absence of tyrosine kinase phosphorylation, and enabled extension of these findings to p38 MAPK. These results suggest that stimulation of ERK1/2 phosphorylation by IGF-1 does not require activation of the receptor tyrosine kinase.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2010.12.008DOI Listing

Publication Analysis

Top Keywords

tyrosine kinase
24
receptor tyrosine
20
erk1/2 activation
12
igf-1 receptor
12
erk1/2 phosphorylation
12
kinase
9
erk1/2
9
extracellular-regulated kinase
8
receptor
8
kinase erk1/2
8

Similar Publications

Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.

View Article and Find Full Text PDF

Distinct TYRO3 and PROS1 expression levels contribute to preeclampsia pathogenesis.

Histochem Cell Biol

January 2025

Departments of Obstetrics and Gynecology, School of Medicine, Akdeniz University, Antalya, Turkey.

Preeclampsia (PE) is a severe placental complication occurring after the 20th week of pregnancy. PE is associated with inflammation and an increased immune reaction against the fetus. TYRO3 and PROS1 suppress inflammation by clearing apoptotic cells.

View Article and Find Full Text PDF
Article Synopsis
  • Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
  • In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
  • The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
View Article and Find Full Text PDF

Flotillins in membrane trafficking and physiopathology.

Biol Cell

January 2025

CRBM (Centre de Recherche en Biologie cellulaire de Montpellier), BIOLuM, University of Montpellier, CNRS UMR 5237, Montpellier, France.

Flotillin 1 and 2 are highly conserved and homologous members of the stomatin, prohibitin, flotillin, HflK/C (SPFH) family. These ubiquitous proteins assemble into hetero-oligomers at the cytoplasmic membrane in sphingolipid-enriched domains. Flotillins play crucial roles in various cellular processes, likely by concentrating sphingosine.

View Article and Find Full Text PDF

Introduction: Adults with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP-ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph- BCP-ALL, and second or third-generation tyrosine kinase inhibitors (TKIs) can produce high remission rates in Ph+ leukaemias. We aimed to assess the activity of blinatumomab and TKI in combination with intensive chemotherapy in the relapsed or refractory setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!